Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection
Status:
Completed
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of VE303 for participants with primary C.
difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C.
difficile infections (rCDI).